Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)

China flag China · Delayed Price · Currency is CNY
12.17
-0.11 (-0.90%)
Apr 29, 2026, 3:04 PM CST
-27.06%
Market Cap 11.67B
Revenue (ttm) 2.38B
Net Income (ttm) 559.77M
Shares Out 950.40M
EPS (ttm) 0.60
PE Ratio 20.64
Forward PE 11.98
Dividend 0.38 (3.15%)
Ex-Dividend Date n/a
Volume 8,059,471
Average Volume 6,680,418
Open 12.63
Previous Close 12.28
Day's Range 11.83 - 12.63
52-Week Range 12.10 - 19.13
Beta 0.54
RSI 31.35
Earnings Date Apr 29, 2026

About SHE:000403

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in research, development, production, and sales of blood products in China and internationally. The company offers human serum albumin, intravenous human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus and anti-tetanus human immunoglobulin, rabies patient immunoglobulin, human coagulation factor VIII, and human prothrombin complex; and freeze-dried intravenous human immunoglobulin (pH4), human fibrinogen, and intravenous hepat... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 2,635
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 000403
Full Company Profile

Financial Performance

In 2025, SHE:000403's revenue was 2.63 billion, a decrease of -0.83% compared to the previous year's 2.65 billion. Earnings were 419.27 million, a decrease of -43.75%.

Financial Statements

News

There is no news available yet.